EXANE DERIVATIVES - TG THERAPEUTICS INC ownership

TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 177 filers reported holding TG THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.0%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of TG THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$53,681,000
-70.0%
5,645
+5.2%
0.02%
-65.1%
Q3 2021$178,641,000
-48.3%
5,368
-39.9%
0.04%
-44.9%
Q2 2021$345,622,000
-19.7%
8,9310.0%0.08%
-36.6%
Q1 2021$430,455,000
-28.6%
8,931
-22.9%
0.12%
-30.5%
Q4 2020$602,468,000
+118.7%
11,582
+12.5%
0.18%
+121.2%
Q3 2020$275,452,000
-3.0%
10,294
-29.4%
0.08%
+5.3%
Q2 2020$283,999,000
+56.5%
14,580
-20.9%
0.08%
+49.0%
Q1 2020$181,422,000
+2859.1%
18,438
+4138.6%
0.05%
+5000.0%
Q4 2019$6,131,000
+151.1%
4350.0%0.00%
Q3 2019$2,442,000
-35.1%
4350.0%0.00%
-100.0%
Q2 2019$3,761,000
+7.6%
4350.0%0.00%0.0%
Q1 2019$3,496,000
+96.1%
4350.0%0.00%
Q4 2018$1,783,000
-32.5%
4350.0%0.00%
Q3 2018$2,642,000
-98.0%
435
-95.6%
0.00%
-100.0%
Q2 2018$132,211,000
-5.0%
9,8340.0%0.02%
-21.4%
Q1 2018$139,098,0009,8340.03%
Other shareholders
TG THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,890,000$15,800,4005.14%
Ghost Tree Capital, LLC 1,000,000$8,360,0002.75%
Soleus Capital Management, L.P. 2,884,382$24,113,4342.22%
M28 Capital Management LP 216,600$1,810,7762.08%
Paradigm Biocapital Advisors LP 3,619,015$30,254,9652.05%
683 Capital Management, LLC 1,350,000$11,286,0000.88%
Parkwood LLC 165,414$6,0810.66%
Spotlight Asset Group, Inc. 79,000$660,4400.60%
Pier Capital, LLC 392,709$3,283,0470.53%
Quantum Private Wealth, LLC 91,081$761,4380.36%
View complete list of TG THERAPEUTICS INC shareholders